23andMe CEO Considers Taking DNA Tester Private
The personalized DNA revolution falls short as a company's stock plummets by 90%. Valued at $3.5 billion, it seeks potential ...
- Latest
- Trending
The personalized DNA revolution falls short as a company's stock plummets by 90%. Valued at $3.5 billion, it seeks potential ...
Consider investing in AbbVie and e.l.f., two names with significant growth potential in 2024. AbbVie shines as a quality business ...
A lawsuit is underway as the misuse of #ivermectin as a COVID treatment continues. The article discusses the legal ramifications ...
Oxford University's DrugGPT, an AI tool to tackle prescription issues, could revolutionize healthcare, preventing mistakes, improving compliance, and reducing expenses.
Pfizer's interest in the weight loss market is uncertain due to its significant debt of over $70 billion and recent ...
Investors seeking a blend of growth, income, and value should consider Viking, Brookfield Renewable, and UPS. While UPS faced a ...
The U.S. lacks AI regulations, but is making progress in implementing safeguards. The Biden Administration introduced new guidance measures for ...
Delve into a comprehensive financial analysis of Cabaletta Bio Inc, a key player in the NASDAQ exchange, with a strong ...
Amazon Pharmacy is leveraging AI for its same-day delivery service expansion in New York City and Los Angeles. AI helps ...
Stay updated on the latest in biotech with our newsletter and podcast. Boundless becomes the ninth biotech company to go ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.